Tag: Beta thalassemia

In December 2023, the U.S. Food and Drug Administration (FDA) approved the world's first CRISPR-based therapy, Casgevy, marking a historic shift in treating genetic blood disorders. This groundbreaking approach directly modifies a patient's own cells, which is central to understanding what is the active ingredient in Casgevy.

In a landmark decision in late 2023, the U.S. FDA approved Casgevy, the first treatment utilizing CRISPR technology to receive authorization. Understanding **how does casgevy gene therapy work** involves a look at its process of gene editing to enable a patient's body to produce healthy blood cells.